Estrella Immunopharma, Inc. (ESLA)
NASDAQ
Closed
Oct 8, 2026
Day's Range
0.361152 wk Range
0.3611Profile - ESLA - Estrella Immunopharma, Inc.
Profile
Mic Code
XNCM
Sector
Healthcare
Industry
Biotechnology
Employees
0
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases. The company is centered on CD19- and CD22-targeted ARTEMIS T-cell programs designed to harness the immune system’s ability to recognize and attack diseased cells. Its current pipeline includes EB103 and EB104 for B-cell malignancies, along with EB201, which is being explored for systemic lupus erythematosus. Estrella Immunopharma operates in the advanced immunotherapy and cell therapy segment of the biopharmaceutical market, where it aims to address treatment challenges through engineered immune-based approaches. Headquartered in Emeryville, California, Estrella Immunopharma is positioned as a research-driven company developing next-generation therapies for oncology and autoimmune disorders.
Profile Details
Type
Common Stock
Address
5858 Horton Street
City
EmeryVille
State
CA
Zip
94608
Country
United States
Phone
510 318 9098
Key Executives - ESLA - Estrella Immunopharma, Inc.
Key executives
Cross Listings - ESLA - Estrella Immunopharma, Inc.
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
